Evidence map›Paper›PMID 34730393›Full record

ArticleJournal of virology2022

Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies.

Dieter Mielke, Sherry Stanfield-Oakley, Bhavesh Borate, Leigh H Fisher, Katelyn Faircloth, Marina Tuyishime, Kelli Greene, Hongmei Gao, Carolyn Williamson, Lynn Morris and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Dieter Mielke *Department of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.ORCID 0000-0003-2182-0510
Sherry Stanfield-Oakley *Department of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
Bhavesh Borate *Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Centergrid.270240.3, Seattle, Washington, USA.
Leigh H FisherVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Centergrid.270240.3, Seattle, Washington, USA.
Katelyn FairclothDepartment of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
Marina TuyishimeDepartment of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.ORCID 0000-0002-6940-3639
Kelli GreeneDepartment of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
Hongmei GaoDepartment of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
Carolyn WilliamsonDivision of Medical Virology, Department of Pathology, University of Cape Towngrid.7836.a, Cape Town, South Africa.
Lynn MorrisNational Health Laboratory Services, Johannesburg, South Africa.
Christina OchsenbauerDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Georgia TomarasDepartment of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
Barton F HaynesDepartment of Immunology, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
David MontefioriDepartment of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
Justin PollaraDepartment of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
Allan C deCamp *Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Centergrid.270240.3, Seattle, Washington, USA.
Guido Ferrari *Department of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
Duke University · USFred Hutch Cancer Center · USNational Health Laboratory Service · ZAUniversity of Alabama at Birmingham · US

Funding

LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Combined Hepatitis B and HIV-1 envelope vaccination to augment T cell help via linked recognition of unrelated antigensK01OD024877 · OD · DUKE UNIVERSITY · PI POLLARA, JUSTIN JOSEPH · 2017 to 2019
$1.0M
NIAID NIH HHS P30 AI064518NIAID NIH HHS UM1 AI068618NIH HHS K01 OD024877
6 · The paper itself

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) has been correlated with reduced risk of human immunodeficiency virus type 1 (HIV-1) infection in several preclinical vaccine trials and in the RV144 clinical trial, indicating that this is a relevant antibody function to study. Given the diversity of HIV-1, the breadth of vaccine-induced antibody responses is a critical parameter to understand if a universal vaccine is to be realized. Moreover, the breadth of ADCC responses can be influenced by different vaccine strategies and regimens, including adjuvants. Therefore, to accurately evaluate ADCC and to compare vaccine regimens, it is important to understand the range of HIV Envelope (Env) susceptibility to these responses. These evaluations have been limited because of the complexity of the assay and the lack of a comprehensive panel of viruses for the assessment of these humoral responses. Here, we used 29 HIV-1 infectious molecular clones (IMCs) representing different Envelope subtypes and circulating recombinant forms to characterize susceptibility to ADCC from antibodies in plasma from infected individuals, including 13 viremic individuals, 10 controllers, and six with broadly neutralizing antibody responses. We found in our panel that ADCC susceptibility of the IMCs in our panel did not cluster by subtype, infectivity, level of CD4 downregulation, level of shedding, or neutralization sensitivity. Using partitioning around medoids (PAM) clustering to distinguish smaller groups of IMCs with similar ADCC susceptibility, we identified nested panels of four to eight IMCs that broadly represent the ADCC susceptibility of the entire 29-IMC panel. These panels, together with reagents developed to specifically accommodate circulating viruses at the geographical sites of vaccine trials, will provide a powerful tool to harmonize ADCC data generated across different studies and to detect common themes of ADCC responses elicited by various vaccines.

Indexed as

Antibody-Dependent Cell CytotoxicityAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusGenetic VariationHIV-1HIV AntibodiesHIV InfectionsHumansNeutralization TestsPhylogenyAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV Antibodiesantibody dependent cellular cytotoxicityhuman immunodeficiency virus

Identifiers

PMID34730393
PMCPMC8791251
OpenAlexW3211309303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.